Is Omeros Corporation (OMER) a Buy, Sell, or Hold?
NASDAQ : OMER
Omeros Corporation
$11.87 USD
-$0.06 (-0.5%)
- Volume
- 609.35K
- Average Volume
- 1.85M
- Market Capitalization
- $859.1M
- P/E Ratio
- 9.13
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $17.65
- Year Low
- $3.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.03
Company Overview
NASDAQ
Gregory A. Demopulos
Biotechnology
Healthcare
OMER
175
US
USD
Liquidity Metrics
-4.90
3.03
3.03
0.03
0.00
Sales & Valuation
-$
86.84
-13.48
-9.06
-1.32
Profitability
-$0.0527
-$3.35M
871.02%
870.07%
-54.39%
30.11%
P/E Metrics
9.13
0.00
0.00
Analyst Price Target & Rating
$33.00
$33.00
$33.00
2/5
19 Analysts
-64.03%
Financial Health Scores
-1.11
6/9
$120.91M
$286.17M
$349.51M
$91.98M
Key Metrics (TTM)
$1.17B
118.48
12.62
3.03
-54.39%
-40.60%
10.04%
-10.98%
1214 days
Company Executives
| Name | Title |
|---|---|
| Peter Cancelmo | Vice President, General Counsel & Corporate Secretary |
| Catherine A. Melfi | Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems |
| Peter W. Williams | Vice President of Human Resources |
| George A. Gaitanaris | Chief Scientific Officer & Vice President of Science |
| Gregory A. Demopulos | Co-Founder, Chairman, Chief Executive Officer & President |
| David J. Borges | Vice President of Finance, Chief Accounting Officer & Treasurer |
| Pamela Pierce Palmer | Co-Founder |
| David W. Ghesquiere | Vice President & Chief Business Development Officer |
Poll Results
No votes yet today — be the first to share your view!
About Omeros Corporation (NASDAQ:OMER) Stock
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation ... for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
2026-07-30 10:00:00
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-28 16:50:00
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-23 10:00:00
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-21 12:56:00
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-16 10:00:00
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-07-14 17:03:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Omeros Corporation Investigated by the Portnoy Law Firm
2026-07-13 14:16:00
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
2026-07-09 19:57:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Omeros Corporation (OMER) stock price?
-
Omeros Corporation(NASDAQ:OMER) stock price is $11.87 in the last trading session. During the trading session, OMER stock reached the peak price of $17.65 while $3.44 was the lowest point it dropped to. The percentage change in OMER stock occurred in the recent session was --0.5% while the dollar amount for the price change in OMER stock was -$0.06.
-
OMER's industry and sector of operation?
-
The NASDAQ listed OMER is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OMER?
-
Peter Cancelmo | Vice President, General Counsel & Corporate Secretary
Catherine A. Melfi | Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems
Peter W. Williams | Vice President of Human Resources
George A. Gaitanaris | Chief Scientific Officer & Vice President of Science
Gregory A. Demopulos | Co-Founder, Chairman, Chief Executive Officer & President -
How many employees does OMER have?
-
Number of OMER employees currently stands at 175. OMER operates from The Omeros Building, Seattle, WA 98119, US.
-
Link for OMER official website?
-
Official Website of OMER is: https://www.omeros.com
-
How do I contact OMER?
-
OMER could be contacted at phone #206 676 5000 and can also be accessed through its website. OMER operates from The Omeros Building, Seattle, WA 98119, US.
-
How many shares of OMER are traded daily?
-
The average number of OMER shares traded daily for last 3 months was 1.85M.
-
What is the market cap of OMER currently?
-
The market value of OMER currently stands at $859.1M with its latest stock price at $11.87